Clinical trial

Real-World Study on Gene Profile in Patients With Advanced NSCLC Who Progressed on First-Line Osimertinib Therapy(GPS).

NCT05219162

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

GENETIC · Unmapped registry intervention Gene Profile explore Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Real-World Study on Gene Profile in Patients With Advanced NSCLC Who Progressed on First-Line Osimertinib Therapy(GPS).

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE4

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2022-02-25

PhasePHASE4

Conditions

Advanced NSCLCunresolved

Interventions

Gene Profile exploreGENETIC

Sponsors & collaborators

AstraZenecalead sponsor

Mapped research locations

BeijingChina1 ShanghaiChina1 TianjinChina1 ChengduChina1 ChangshaChina1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05219162 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.